RIGL vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RIGL Captures Institutional Edge (3โ1 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Rigel Pharmaceuticals Inc. (New) (RIGL) driven by superior Valuation, Growth & Margin, Options & Structure while DMAC counters with relative strength in Momentum & Technical. Fundamentally, RIGL trades at 9.3x Forward P/E with 26.3% operating margin (+16.5% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RIGL sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RIGL Revenue | DMAC Revenue | RIGL Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $40M | $0M | -163.3% | -1352.2% | RIGL |
| FY2019 | $60M | N/A | -116.5% | N/A | RIGL |
| FY2020 | $110M | N/A | -26.7% | N/A | RIGL |
| FY2021 | $150M | N/A | -8.4% | N/A | RIGL |
| FY2022 | $120M | N/A | -46.2% | N/A | RIGL |
| FY2023 | $120M | N/A | -17.5% | N/A | RIGL |
| FY2024 | $180M | N/A | 13.5% | N/A | RIGL |
| FY2025 | $290M | N/A | 42.6% | N/A | RIGL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RIGL | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $860.3M | $503.1M | Larger Scale | RIGL |
| Trailing P/E Ratio Valuation | 2.8x | N/M | Lower Multiple | RIGL |
| Forward P/E Ratio Valuation | 9.3x | N/M | Lower Multiple | RIGL |
| Revenue Growth (YoY) Growth | +16.5% | +0.0% | Higher Growth | RIGL |
| Operating Margin (TTM) Profitability | 26.3% | 0.0% | Higher Margin | RIGL |
| Net Profit Margin Profitability | 106.6% | 0.0% | Higher Margin | RIGL |
| Return on Equity (ROE) Capital Efficiency | 109.2% | -114.6% | Higher ROE | RIGL |
| 52-Week Range Position Momentum | 68% ($25โ$53) | 55% ($5โ$11) | Stronger Trend | RIGL |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 74% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | RIGL |
| Unified Institutional Score Composite Signal | 59.9 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | RIGL |